PRECISION BIOSCIENCES INC — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Effective August 1, 2026, Alex Kelly (current CFO) promoted to newly created Chief Operating Officer role overseeing customer-facing functions; Naresh Tanna (VP Investor Relations/Chief of Staff) promoted to CFO overseeing finance and investor relations. Two new physician leaders hired under CDO Cindy Atwell to support PBGENE-HBV and PBGENE-DMD clinical programs. No severance, departures, or financial impacts disclosed.
Why this rating
Internal promotions + two hires in clinical-stage biotech are routine management restructuring. No departures, no financial impact, no clinical delays disclosed. Immaterial relative to $47M market cap.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.